Who is sponsoring NCT05754983?

NCT05754983 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What condition does NCT05754983 study?

NCT05754983 studies Malignant Neoplasm.

Is NCT05754983 still recruiting?

NCT05754983 is currently active, enrolled. Last updated 7 February 2025.

Last reviewed 2025-02-07 · How we verify

NCT05754983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Risk Factors and Long-term Impact of ICIs

Active, enrolled Last updated 7 February 2025

What this trial tests

trial testing Solid tumor patients receiving immunotherapy for the first time were included in the study in Malignant Neoplasm in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 November 2022

Primary endpoint
30 December 2024

31 December 2025

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	24 November 2022
Primary completion	30 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Solid tumor patients receiving immunotherapy for the first time were included in the study — full drug profile →

Conditions studied

Malignant Neoplasm — all drugs for Malignant Neoplasm →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 18 to 80, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study plans to conduct a multicenter, observable and controlled cohort study to solid-tumor patients with receiving immunotherapy and to collect information about their treatment related efficacy, adverse events and health status to build a disease cohort database based on patient reports, and then analyze the risk factors affecting the efficacy, prognosis and adverse events of immunotherapy and the impact of immunotherapy on health status. It is expected to provide high-level evidence-based medical evidence for the selection of immunotherapy schemes for these patients, the precise prevention and health management of adverse events after immunotherapy, and the further improvement of survival prognosis of patients

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Long-term impact of COVID-19 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter cohort study during Omicron pandemic.
Zhang Y, Li Y, Zhang Y, Zhang T, et al · · 2025 · cited 1× · PMID 41013305 · DOI 10.1186/s12879-025-11544-8
Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study.
Li Y, Jia X, Liu M, Zhu Z, et al · · 2026 · PMID 41922087 · DOI 10.1136/jitc-2025-014360

Verify or expand the search:

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05754983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 7 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05754983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing